Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 2021 Aug 20;218(10):jem.2021121108132021c. doi: 10.1084/jem.2021121108132021c

Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

Jonathan Lopez, Marine Mommert, William Mouton, Andrés Pizzorno, Karen Brengel-Pesce, Mehdi Mezidi, Marine Villard, Bruno Lina, Jean-Christophe Richard, Jean-Baptiste Fassier, Valérie Cheynet, Blandine Padey, Victoria Duliere, Thomas Julien, Stéphane Paul, Paul Bastard, Alexandre Belot, Antonin Bal, Jean-Laurent Casanova, Manuel Rosa-Calatrava, Florence Morfin, Thierry Walzer, Sophie Trouillet-Assant
PMCID: PMC8493864  PMID: 34415984

Vol. 218, No. 10 | 10.1084/jem.20211211 | August 6, 2021

The authors regret that in the original version of this paper, Hadjadj et al. (2020) was cited instead of Bastard et ala. (2020) in a sentence about auto-Abs in the Introduction. The corrected sentence is below.

“This defect is explained in some patients by inborn genetic defects of IFN-I induction or amplification (Zhang et al., 2020b) and in others by the presence of neutralizing autoantibodies (auto-Abs) against type I IFNs, mainly IFN-α and/or IFN-ω and, in rare cases, IFN-β (Bastard et al., 2020).”

The error appears only in PDFs downloaded before August 10, 2021.


Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES